HIV and Hepatitis B Coinfection Among Perinatally HIV-infected Thai Adolescents

Overview

Journal Pediatr Infect Dis J

Specialty Pediatrics

Date 2012 May 18

PMID 22592516

Citations 11

Authors

Linda Aurpibul

Pagakrong Lumbiganon

Pope Kolasaraksa

Rawiwan Hansudewechakul

Pattaratida Sa-Nguanmoo

Pawinee Taeprasert

Torsak Bunupuradah

Yong Poovorawan

Virat Sirisanthana

Thanyawee Puthanakit

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aimed to determine the prevalence of hepatitis B virus (HBV) coinfection and HBV seropositivity in perinatally HIV-infected adolescents. A secondary objective was to describe the clinical characteristics of adolescents with chronic HBV/HIV coinfection.

Materials And Methods: Multicenter cross-sectional study of perinatally HIV-infected adolescents aged 12-25 years. HBV surface antigen, surface antibody (anti-HBs) and core antibody (anti-HBc) were measured. Coinfection was defined as having persistently positive HBV surface antigen. Seroprotective antibody from immunization was defined as having anti-HBs ≥10 mIU/mL with negative anti-HBc. HBV DNA quantitation and rtM204V/I mutation analysis (lamivudine resistance-associated mutation) were performed in adolescents with chronic HBV infection.

Results: From November 2010 to March 2011, 521 patients were enrolled. Mean (SD) of CD4 lymphocyte count was 685 (324) cells/μL. The prevalence of HBV/HIV coinfection was 3.3% (95% confidence interval: 1.9-5.2%). Protective antibody against HBV was found in 18% of population, and this was significantly higher among adolescents who received than those who did not receive HBV revaccination after receiving antiretroviral therapy (93% versus 6%, P < 0.01). Among adolescents with chronic HBV infection, 88% have received lamivudine; however, 69% have HBV DNA >10 copies/mL and 75% had the rtM204V/I mutation.

Conclusions: The prevalence of HBV coinfection in HIV-infected Thai adolescents was 3.3%. Most HIV-infected adolescents had no HBV protective antibody; therefore, revaccination with HBV vaccine is encouraged. The high prevalence of HBV-lamivudine resistance underscores the importance of HBV screening prior to antiretroviral therapy initiation to guide the selection of optimal regimen for coinfected children.

Citing Articles

Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis.

Platt L, French C, McGowan C, Sabin K, Gower E, Trickey A J Viral Hepat. 2019; 27(3):294-315.

PMID: 31603999 PMC: 7383613. DOI: 10.1111/jvh.13217.

Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen.

Aurpibul L, Kanjanavanit S, Leerapun A, Puthanakit T J Int Assoc Provid AIDS Care. 2019; 18:2325958218823259.

PMID: 30798669 PMC: 6748531. DOI: 10.1177/2325958218823259.

Seroprevalence of Hepatitis B Among HIV-infected Children and Adolescents Receiving Antiretroviral Therapy in the TREAT Asia Pediatric HIV Observational Database.

Aurpibul L, Kariminia A, Vibol U, Siew Fong M, Le O, Hansudewechakul R Pediatr Infect Dis J. 2018; 37(8):788-793.

PMID: 29846357 PMC: 6097529. DOI: 10.1097/INF.0000000000001901.

Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents.

Aurpibul L, Lumbiganon P, Hansudewechakul R, Kanjanavanit S, Bunupuradah T, Kosalaraksa P Pediatr Infect Dis J. 2016; 36(4):401-404.

PMID: 28005687 PMC: 5348266. DOI: 10.1097/INF.0000000000001491.

Pediatric HIV-HBV Coinfection in Lusaka, Zambia: Prevalence and Short-Term Treatment Outcomes.

Peebles K, Nchimba L, Chilengi R, Moore C, Mubiana-Mbewe M, Vinikoor M J Trop Pediatr. 2015; 61(6):464-7.

PMID: 26338421 PMC: 4852213. DOI: 10.1093/tropej/fmv058.

References

Piroth L, Sene D, Pol S, Goderel I, Lacombe K, Martha B . Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS. 2007; 21(10):1323-31. DOI: 10.1097/QAD.0b013e32810c8bcf. View

Sa-Nguanmoo P, Tangkijvanich P, Thawornsuk N, Vichaiwattana P, Prianantathavorn K, Theamboonlers A . Molecular epidemiological study of hepatitis B virus among migrant workers from Cambodia, Laos, and Myanmar to Thailand. J Med Virol. 2010; 82(8):1341-9. DOI: 10.1002/jmv.21828. View

Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J . Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS. 2005; 19(3):221-40. View

Zhou S, Zhao Y, He Y, Li H, Bulterys M, Sun X . Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009. J Acquir Immune Defic Syndr. 2009; 54(2):191-6. PMC: 2877757. DOI: 10.1097/QAI.0b013e3181c99226. View

Jack A, Hall A, Maine N, Mendy M, Whittle H . What level of hepatitis B antibody is protective?. J Infect Dis. 1999; 179(2):489-92. DOI: 10.1086/314578. View

McGovern B . The epidemiology, natural history and prevention of hepatitis B: implications of HIV coinfection. Antivir Ther. 2008; 12 Suppl 3:H3-13. View

Chongsrisawat V, Yoocharoen P, Theamboonlers A, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S . Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health. 2006; 11(10):1496-502. DOI: 10.1111/j.1365-3156.2006.01709.x. View

Matthews G, Avihingsanon A, Lewin S, Amin J, Rerknimitr R, Petcharapirat P . A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology. 2008; 48(4):1062-9. DOI: 10.1002/hep.22462. View

Law W, Duncombe C, Mahanontharit A, Boyd M, Ruxrungtham K, Lange J . Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004; 18(8):1169-77. DOI: 10.1097/00002030-200405210-00010. View

10.

Abzug M, Warshaw M, Rosenblatt H, Levin M, Nachman S, Pelton S . Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2009; 200(6):935-46. PMC: 2814776. DOI: 10.1086/605448. View

11.

Lao-Araya M, Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V . Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine. 2007; 25(29):5324-9. DOI: 10.1016/j.vaccine.2007.05.006. View

12.

McMahon B, Alward W, Hall D, Heyward W, Bender T, Francis D . Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985; 151(4):599-603. DOI: 10.1093/infdis/151.4.599. View

13.

Telatela S, Matee M, Munubhi E . Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania. BMC Public Health. 2007; 7:338. PMC: 2204008. DOI: 10.1186/1471-2458-7-338. View

14.

Sa-Nguanmoo P, Tangkijvanich P, Payungporn S, Chieochansin T, Thawornsuk N, Chongsrisawat V . Dynamics of HBV DNA levels, HBV mutations and biochemical parameters during antiviral therapy in a patient with HBeAg-negative chronic hepatitis B. Asian Pac J Allergy Immunol. 2007; 25(2-3):183-8. View

15.

Benhamou Y, BOCHET M, Thibault V, Di Martino V, Caumes E, Bricaire F . Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999; 30(5):1302-6. DOI: 10.1002/hep.510300525. View

16.

Payungporn S, Tangkijvanich P, Jantaradsamee P, Theamboonlers A, Poovorawan Y . Simultaneous quantitation and genotyping of hepatitis B virus by real-time PCR and melting curve analysis. J Virol Methods. 2004; 120(2):131-40. DOI: 10.1016/j.jviromet.2004.04.012. View

17.

Sulkowski M . Management of hepatic complications in HIV-infected persons. J Infect Dis. 2008; 197 Suppl 3:S279-93. DOI: 10.1086/533414. View

18.

Zhou J, Dore G, Zhang F, Lim P, Chen Y . Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol. 2007; 22(9):1510-8. DOI: 10.1111/j.1440-1746.2007.05062.x. View

19.

Sun H, Lee H, Liu C, Yang C, Su S, Ko W . Factors associated with isolated anti-hepatitis B core antibody in HIV-positive patients: impact of compromised immunity. J Viral Hepat. 2009; 17(8):578-87. DOI: 10.1111/j.1365-2893.2009.01212.x. View

20.

Gandhi R, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R . Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis. 2003; 36(12):1602-5. DOI: 10.1086/375084. View